2019
Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.
Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B, Lin P, Mukherjee B. Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urology Practice 2019, 6: 234-242. PMID: 31276025, PMCID: PMC6605774, DOI: 10.1097/upj.0000000000000020.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen signaling inhibitorsAdvanced prostate cancerFirst-line treatmentProstate cancerSystemic treatment of advanced prostate cancerDatabase of commercially insured patientsTreatment of advanced prostate cancerCastration-resistant prostate cancerSignaling inhibitorsPre-existing heart failureImproved overall survivalTreatment of menCommercially insured patientsSipuleucel-TRadium-223Overall survivalSystemic treatmentTreatment patternsNovel therapiesMedical oncologistsHeart failureMultivariate analysisProvider specialtyDocetaxelTargeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Mohan D, Lerario A, Else T, Mukherjee B, Almeida M, Vinco M, Rege J, Mariani B, Zerbini M, Mendonca B, Latronico A, Marie S, Rainey W, Giordano T, Fragoso M, Hammer G. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research 2019, 25: 3276-3288. PMID: 30770352, PMCID: PMC7117545, DOI: 10.1158/1078-0432.ccr-18-2693.Peer-Reviewed Original ResearchConceptsUpregulation of cell cycleDNA damage response programsAdrenocortical carcinomaTargeted bisulfite sequencingCancer Genome Atlas projectBisulfite sequencingCpG island hypermethylation phenotypeHypermethylation phenotypeAggressive adrenocortical carcinomasCell cycleMolecular markersBiological processesHypermethylationMolecular diagnosticsShorter disease-freeCancers of patientsBiomarker methylationAtlas projectEfficacious adjuvant therapyLocoregional diseaseOverall survivalAdjuvant therapyAdrenocortical tumorsDismal outcomeSilencing
2016
Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Koi M, Garcia M, Choi C, Kim H, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen Y, Mukherjee B, Boland C, Carethers J. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016, 150: 944-955. PMID: 26752111, PMCID: PMC4808397, DOI: 10.1053/j.gastro.2015.12.032.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorChi-Square DistributionChromosome AberrationsChromosomes, Human, Pair 9Colorectal NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansJapanKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Republic of KoreaRisk FactorsTime FactorsTreatment OutcomeConceptsPrimary colorectal tumorsLoss of heterozygosityLiver metastasesColorectal cancerColorectal tumorsElevated microsatellite alterationsMicrosatellite alterationsStage IICurative treatment of patientsStage III colorectal cancerOverall survival of patientsSurvival of patientsIII colorectal cancerTumor to liverColorectal cancer recurrenceTreatment of patientsMatched liver metastasesCancer cell nucleiMatched metastasesDisease recurrenceOverall survivalPrognostic factorsAllelic lossNo significant differenceCurative treatment
2013
Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin L, Fullen D, Giordano T, Thomas D, Frohm M, B. K, Ahn J, Mukherjee B, Johnson T, Gruber S. Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal Of Investigative Dermatology 2013, 133: 2585-2592. PMID: 23633021, PMCID: PMC4267221, DOI: 10.1038/jid.2013.197.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerOverall survivalTissue microarrayPrimary melanomaMelanoma pathogenesisMelanoma progressionAssociated with disease-free survivalAnalysis of tissue microarraysMetastases-free survivalDisease-free survivalHMGA2 overexpressionCox proportional hazards regression modelsLog-rank testPredictors of survivalProportional hazards regression modelsHazards regression modelsBRAF/NRAS mutationsPrimary tumorPrognostic featuresMelanoma metastasesClinicopathological characteristicsReal-time PCRGenetic alterationsAQUA analysisMelanoma development